Bacteraemia – Pipeline Review, 2019

Bacteremia is characterized by the presence of bacteria on an individual’s blood. Bacteremia can be caused by factors like an indwelling catheter, surgery, tissue wound among others. The infection can be short-termed or can lead to serious complications like sepsis or septic shock if not treated properly. Bacteremia can cause chronic diseases such as meningitis or pneumonia. Certain patients having HIV, diabetes mellitus, undergoing organ transplant and chronic hemodialysis are more susceptible to acquiring bacteremia.

Bacteremia is predominantly treated by antibiotics that target the infection-causing bacteria. Patients that are undergoing surgery or catheterization are pre immunized against bacteremia by antibiotics. Majority of the antibiotics prescribed are generic in nature.

Several research institutes along with pharmaceutical companies have been concentrating on studying and developing novel treatment options for bacteremia as the incidences of antibiotic-resistant bacterial infection is on the rise. For instance; ETX2514, which is being studied by Entasis Therapeutics, Inc., is currently in phase-3 clinical trials for the evaluation of efficacy and safety of ETX2514 in patients infected with Acinetobacter Baumannii-calcoaceticus Complex

As of 2019, approximately 61% of a clinical trial in bacteremia is in Phase 3 and Phase 4 stage. Majority of these clinical studies are carried out by research institutions.

Report Description

The report on ‘Bacteraemia – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Bacteraemia. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Bacteraemia.

The report on ‘Bacteraemia – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

• Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, Research Gate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Bacteraemia
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Bacteraemia
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary